---
document_datetime: 2025-12-02 04:55:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-viatris.html
document_name: duloxetine-viatris.html
version: success
processing_time: 0.145262
conversion_datetime: 2025-12-28 03:17:36.819748
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Duloxetine Viatris (previously Duloxetine Mylan)

[RSS](/en/individual-human-medicine.xml/67006)

##### Authorised

This medicine is authorised for use in the European Union

duloxetine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Duloxetine Viatris (previously Duloxetine Mylan)](#news-on)
- [More information on Duloxetine Mylan](#more-information-on-duloxetine-mylan-1508)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80203)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Duloxetine Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Mylan.

For practical information about using Duloxetine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Duloxetine Mylan and what is it used for?

Duloxetine Mylan is used to treat adults with the following diseases:

- major depression;
- pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes);
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

Duloxetine Mylan contains the active substance duloxetine and is a 'generic medicine'. This means that Duloxetine Mylan is similar to a 'reference medicine' already authorised in the European Union (EU) called Cymbalta.

## How is Duloxetine Mylan used?

Duloxetine Mylan is available as gastroresistant capsules (30 and 60 mg). 'Gastroresistant' means that the capsules' contents pass through the stomach without being broken down until they reach the intestine. This prevents the active substance being destroyed by the acid in the stomach. The medicine can only be obtained with a prescription.

For major depression, the recommended dose of Duloxetine Mylan is 60 mg once a day. A response is usually seen in two to four weeks. In patients who respond to Duloxetine Mylan, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.

For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of 120 mg per day. The response to treatment should be assessed regularly.

For generalised anxiety disorder, the recommended starting dose is 30 mg once a day, but the dose can be increased to 60, 90 or 120 mg depending on the patient's response. Most patients will need to take 60 mg per day. Patients who also have major depression should start with 60 mg once a day. In patients who respond to Duloxetine Mylan, treatment should continue for several months, to prevent the disorder coming back.

The dose of Duloxetine Mylan should be reduced gradually when stopping treatment.

## How does Duloxetine Mylan work?

The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor. It works by preventing the neurotransmitters serotonin (5-hydroxytryptamine) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.

Neurotransmitters are chemicals that allow nerve cells to communicate with one another. By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells. Since these neurotransmitters are involved in maintaining high mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.

## How has Duloxetine Mylan been studied?

Because Duloxetine Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Cymbalta. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Duloxetine Mylan?

Because Duloxetine Mylan is a generic medicine of Cymbalta, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Duloxetine Mylan approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Duloxetine Mylan has been shown to have comparable quality and to be bioequivalent to Cymbalta. Therefore, the CHMP's view was that, as for Cymbalta, the benefit outweighs the identified risk. The Committee recommended that Duloxetine Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Duloxetine Mylan?

A risk management plan has been developed to ensure that Duloxetine Mylan is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Duloxetine Mylan : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/duloxetine-mylan-epar-risk-management-plan-summary_en.pdf) .

## Other information about Duloxetine Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Duloxetine Mylan on 19 June 2015.

For more information about treatment with Duloxetine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Duloxetine Mylan : EPAR - Summary for the public

English (EN) (98.3 KB - PDF)

**First published:** 24/06/2015

**Last updated:** 24/06/2015

[View](/en/documents/overview/duloxetine-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-196)

български (BG) (125.85 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/bg/documents/overview/duloxetine-mylan-epar-summary-public_bg.pdf)

español (ES) (98.58 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/es/documents/overview/duloxetine-mylan-epar-summary-public_es.pdf)

čeština (CS) (124.86 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/cs/documents/overview/duloxetine-mylan-epar-summary-public_cs.pdf)

dansk (DA) (97.53 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/da/documents/overview/duloxetine-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (105.2 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/de/documents/overview/duloxetine-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (103.35 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/et/documents/overview/duloxetine-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (130.38 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/el/documents/overview/duloxetine-mylan-epar-summary-public_el.pdf)

français (FR) (104.77 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/fr/documents/overview/duloxetine-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (120.89 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/hr/documents/overview/duloxetine-mylan-epar-summary-public_hr.pdf)

italiano (IT) (103.37 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/it/documents/overview/duloxetine-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (121.71 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/lv/documents/overview/duloxetine-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (123.03 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/lt/documents/overview/duloxetine-mylan-epar-summary-public_lt.pdf)

magyar (HU) (120.83 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/hu/documents/overview/duloxetine-mylan-epar-summary-public_hu.pdf)

Malti (MT) (126.27 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/mt/documents/overview/duloxetine-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (104.45 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/nl/documents/overview/duloxetine-mylan-epar-summary-public_nl.pdf)

polski (PL) (125.69 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/pl/documents/overview/duloxetine-mylan-epar-summary-public_pl.pdf)

português (PT) (104.51 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/pt/documents/overview/duloxetine-mylan-epar-summary-public_pt.pdf)

română (RO) (121.78 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/ro/documents/overview/duloxetine-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (124.09 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/sk/documents/overview/duloxetine-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (119.2 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/sl/documents/overview/duloxetine-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (102.86 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/fi/documents/overview/duloxetine-mylan-epar-summary-public_fi.pdf)

svenska (SV) (103.39 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

24/06/2015

[View](/sv/documents/overview/duloxetine-mylan-epar-summary-public_sv.pdf)

Duloxetine Mylan : EPAR - Risk-management-plan summary

English (EN) (76.03 KB - PDF)

**First published:** 24/06/2015

**Last updated:** 25/04/2022

[View](/en/documents/rmp-summary/duloxetine-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Duloxetine Viatris : EPAR - Product Information

English (EN) (479.28 KB - PDF)

**First published:** 24/06/2015

**Last updated:** 15/10/2025

[View](/en/documents/product-information/duloxetine-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-796)

български (BG) (817.58 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/bg/documents/product-information/duloxetine-viatris-epar-product-information_bg.pdf)

español (ES) (519.91 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/es/documents/product-information/duloxetine-viatris-epar-product-information_es.pdf)

čeština (CS) (707.53 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/cs/documents/product-information/duloxetine-viatris-epar-product-information_cs.pdf)

dansk (DA) (618.66 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/da/documents/product-information/duloxetine-viatris-epar-product-information_da.pdf)

Deutsch (DE) (552.34 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/de/documents/product-information/duloxetine-viatris-epar-product-information_de.pdf)

eesti keel (ET) (538.96 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/et/documents/product-information/duloxetine-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (792.57 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/el/documents/product-information/duloxetine-viatris-epar-product-information_el.pdf)

français (FR) (711.07 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/fr/documents/product-information/duloxetine-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (671.04 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/hr/documents/product-information/duloxetine-viatris-epar-product-information_hr.pdf)

íslenska (IS) (578.62 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/is/documents/product-information/duloxetine-viatris-epar-product-information_is.pdf)

italiano (IT) (692.04 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/it/documents/product-information/duloxetine-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (660.19 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/lv/documents/product-information/duloxetine-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (634.19 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/lt/documents/product-information/duloxetine-viatris-epar-product-information_lt.pdf)

magyar (HU) (689.79 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/hu/documents/product-information/duloxetine-viatris-epar-product-information_hu.pdf)

Malti (MT) (876.31 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/mt/documents/product-information/duloxetine-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (618.52 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/nl/documents/product-information/duloxetine-viatris-epar-product-information_nl.pdf)

norsk (NO) (325.3 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/no/documents/product-information/duloxetine-viatris-epar-product-information_no.pdf)

polski (PL) (683.45 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/pl/documents/product-information/duloxetine-viatris-epar-product-information_pl.pdf)

português (PT) (604.69 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/pt/documents/product-information/duloxetine-viatris-epar-product-information_pt.pdf)

română (RO) (708.53 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/ro/documents/product-information/duloxetine-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (634.34 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/sk/documents/product-information/duloxetine-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (639.69 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/sl/documents/product-information/duloxetine-viatris-epar-product-information_sl.pdf)

Suomi (FI) (562.27 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/fi/documents/product-information/duloxetine-viatris-epar-product-information_fi.pdf)

svenska (SV) (562.31 KB - PDF)

**First published:**

24/06/2015

**Last updated:**

15/10/2025

[View](/sv/documents/product-information/duloxetine-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000304267 10/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Duloxetine Viatris : EPAR - All Authorised presentations

English (EN) (100.95 KB - PDF)

**First published:** 22/03/2016

**Last updated:** 04/12/2024

[View](/en/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-726)

български (BG) (101.5 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/bg/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.09 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/es/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (80.48 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/cs/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (122.3 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/da/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.42 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/de/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (76.7 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/et/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (163.45 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/el/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (42.64 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/fr/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (156.26 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/hr/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.67 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/is/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (83.58 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/it/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (92.12 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/lv/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (92.18 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/lt/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.91 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/hu/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (104.45 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/mt/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (74.66 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/nl/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (119.48 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/no/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (71.84 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/pl/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.7 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/pt/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (82.92 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/ro/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (113.8 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/sk/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.24 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/sl/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.38 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/fi/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (91.05 KB - PDF)

**First published:**

22/03/2016

**Last updated:**

04/12/2024

[View](/sv/documents/all-authorised-presentations/duloxetine-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Duloxetine Viatris (previously Duloxetine Mylan) Active substance duloxetine International non-proprietary name (INN) or common name duloxetine Therapeutic area (MeSH)

- Neuralgia
- Diabetic Neuropathies
- Depressive Disorder, Major
- Anxiety Disorders

Anatomical therapeutic chemical (ATC) code N06AX21

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

- Treatment of major depressive disorder
- Treatment of diabetic peripheral neuropathic pain
- Treatment of generalised anxiety disorder
- Duloxetine Viatris is indicated in adults

## Authorisation details

EMA product number EMEA/H/C/003981

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 23/04/2015 Marketing authorisation issued 19/06/2015 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Duloxetine Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (328.75 KB - PDF)

**First published:** 15/10/2025

[View](/en/documents/procedural-steps-after/duloxetine-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Duloxetine Viatris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (187.83 KB - PDF)

**First published:** 12/01/2015

**Last updated:** 15/10/2025

[View](/en/documents/procedural-steps-after/duloxetine-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Duloxetine Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/238550/2015

English (EN) (784.41 KB - PDF)

**First published:** 24/06/2015

**Last updated:** 24/06/2015

[View](/en/documents/assessment-report/duloxetine-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Duloxetine Mylan

Adopted

Reference Number: EMA/CHMP/238545/2015

English (EN) (65.64 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 24/04/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-duloxetine-mylan_en.pdf)

#### News on Duloxetine Viatris (previously Duloxetine Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

#### More information on Duloxetine Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Duloxetine Viatris (previously Duloxetine Mylan) : EPAR - Product information - tracked changes

English (EN) (161.86 KB - DOCX)

**First published:** 15/10/2025

[View](/en/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-790)

български (BG) (211.92 KB - DOCX)

**First published:**

15/10/2025

[View](/bg/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (155.88 KB - DOCX)

**First published:**

15/10/2025

[View](/es/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (383.28 KB - DOCX)

**First published:**

15/10/2025

[View](/cs/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (167.08 KB - DOCX)

**First published:**

15/10/2025

[View](/da/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (159.63 KB - DOCX)

**First published:**

15/10/2025

[View](/de/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (138.2 KB - DOCX)

**First published:**

15/10/2025

[View](/et/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (207.67 KB - DOCX)

**First published:**

15/10/2025

[View](/el/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (188.87 KB - DOCX)

**First published:**

15/10/2025

[View](/fr/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (165.18 KB - DOCX)

**First published:**

15/10/2025

[View](/hr/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (165.43 KB - DOCX)

**First published:**

15/10/2025

[View](/is/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_is.docx)

italiano (IT) (187.59 KB - DOCX)

**First published:**

15/10/2025

[View](/it/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (151.64 KB - DOCX)

**First published:**

15/10/2025

[View](/lv/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (144.03 KB - DOCX)

**First published:**

15/10/2025

[View](/lt/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (159.44 KB - DOCX)

**First published:**

15/10/2025

[View](/hu/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (175.71 KB - DOCX)

**First published:**

15/10/2025

[View](/mt/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (171.95 KB - DOCX)

**First published:**

15/10/2025

[View](/nl/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (163.46 KB - DOCX)

**First published:**

15/10/2025

[View](/no/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_no.docx)

polski (PL) (161.54 KB - DOCX)

**First published:**

15/10/2025

[View](/pl/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_pl.docx)

português (PT) (138.54 KB - DOCX)

**First published:**

15/10/2025

[View](/pt/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (185.3 KB - DOCX)

**First published:**

15/10/2025

[View](/ro/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (148.02 KB - DOCX)

**First published:**

15/10/2025

[View](/sk/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (160.38 KB - DOCX)

**First published:**

15/10/2025

[View](/sl/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (181.69 KB - DOCX)

**First published:**

15/10/2025

[View](/fi/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (158.68 KB - DOCX)

**First published:**

15/10/2025

[View](/sv/documents/product-information-tracked-changes/duloxetine-viatris-previously-duloxetine-mylan-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/10/2025

## Share this page

[Back to top](#main-content)